SAB Biotherapeutics (SABS) Change in Account Payables (2021 - 2026)

SAB Biotherapeutics (SABS) has 6 years of Change in Account Payables data on file, last reported at $114119.0 in Q1 2026.

• Quarterly Change in Account Payables fell 83.32% year-over-year to $114119.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $912741.0 (down 33.09% YoY) and the FY2025 annual result came in at $1.5 million, up 60.59% from the prior year.
• Change in Account Payables retreated to $114119.0 in Q1 2026, from $324527.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $684171.0 in Q1 2025 to a low of -$2.2 million in Q1 2023.
• A 5-year average of -$11490.8 and a median of $124368.5 in 2024 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2022 — Change in Account Payables jumped 3216.08% — and 2023, when it plunged 527.33%.
• Tracing SABS's Change in Account Payables over 5 years: stood at -$487425.0 in 2022, then jumped by 78.3% to -$105773.0 in 2023, then jumped by 658.16% to $590385.0 in 2024, then plunged by 45.03% to $324527.0 in 2025, then tumbled by 64.84% to $114119.0 in 2026.
• The last three Change in Account Payables figures came in at $114119.0 (Q1 2026), $324527.0 (Q4 2025), and $335924.0 (Q3 2025), per Business Quant data.